Ionis Pharmaceuticals IONS Debt Issuance Cost Amortization
Debt Issuance Cost Amortization at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's debt issuance cost amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's debt issuance cost amortization?
- Ionis Pharmaceuticals (IONS) reported debt issuance cost amortization of $2.35M in Q1 2026.
- How has Ionis Pharmaceuticals's debt issuance cost amortization changed year-over-year?
- Ionis Pharmaceuticals's debt issuance cost amortization increased by 43.1% year-over-year, from $1.64M to $2.35M.
- What is the long-term trend for Ionis Pharmaceuticals's debt issuance cost amortization?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's debt issuance cost amortization has grown at a 8.6% compound annual growth rate (CAGR), from $4.96M to $6.91M.
- What does debt issuance cost amortization mean?
- The non-cash expense of spreading out the upfront costs of obtaining debt over the life of the loan.
- How do you interpret debt issuance cost amortization?
- Higher levels indicate larger or more frequent debt issuances, reflecting the company's financing activity.
- How does debt issuance cost amortization compare across companies?
- Standard for any company with significant long-term debt on the balance sheet.